A carregar...
The development of PARP inhibitors in ovarian cancer: from bench to bedside
The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olapar...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4816267/ https://ncbi.nlm.nih.gov/pubmed/26669452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.394 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|